Literature DB >> 6209769

Group A meningococcal disease in the U.S. Pacific Northwest: epidemiology, clinical features, and effect of a vaccination control program.

G W Counts, D F Gregory, J G Spearman, B A Lee, G A Filice, K K Holmes, J M Griffiss.   

Abstract

In 1975 an outbreak of group A meningococcal disease began in Seattle, Washington, and cases subsequently were recognized throughout the Pacific Northwest. Nearly one-half of the affected persons were Native Americans; two-thirds were alcohol abusers and/or habitués of skid road communities. In Seattle, group A meningococci colonized asymptomatic persons only if these individuals had contact with skid road (P = .006). The epidemic strain may have spread from American Indians in Manitoba, Canada. Traditional migration routes connect the two populations; asymptomatic American Indians on reservations in Washington carried group A meningococci. Vaccination programs were undertaken in four cities but only after cases occurred. In Seattle, vaccination reached 80% of the target population and was associated with a significant decrease in incidence of the disease, but cases recurred after the program ended. The social habits of skid road communities, combined with the "case-triggering" approach to, and premature termination of, vaccination programs, may have resulted in 56% of regional cases occurring after the start of the vaccination program in Seattle.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6209769     DOI: 10.1093/clinids/6.5.640

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  11 in total

1.  Clonal and antigenic analysis of serogroup A Neisseria meningitidis with particular reference to epidemiological features of epidemic meningitis in the People's Republic of China.

Authors:  J F Wang; D A Caugant; X Li; X Hu; J T Poolman; B A Crowe; M Achtman
Journal:  Infect Immun       Date:  1992-12       Impact factor: 3.441

Review 2.  Global epidemiology of meningococcal disease.

Authors:  B Schwartz; P S Moore; C V Broome
Journal:  Clin Microbiol Rev       Date:  1989-04       Impact factor: 26.132

Review 3.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

4.  Emergence of Bartonella quintana infection among homeless persons.

Authors:  L A Jackson; D H Spach
Journal:  Emerg Infect Dis       Date:  1996 Apr-Jun       Impact factor: 6.883

5.  Risk of group A meningococcal disease: bacterial interference and cross-reactive bacteria among mucosal flora.

Authors:  G A Filice; P S Hayes; G W Counts; J M Griffiss; D W Fraser
Journal:  J Clin Microbiol       Date:  1985-08       Impact factor: 5.948

6.  Physical heterogeneity of neisserial lipooligosaccharides reflects oligosaccharides that differ in apparent molecular weight, chemical composition, and antigenic expression.

Authors:  J M Griffiss; J P O'Brien; R Yamasaki; G D Williams; P A Rice; H Schneider
Journal:  Infect Immun       Date:  1987-08       Impact factor: 3.441

7.  Measurement of the human immune response to meningococcal lipooligosaccharide antigens by using serum to inhibit monoclonal antibody binding to purified lipooligosaccharide.

Authors:  M M Estabrook; R E Mandrell; M A Apicella; J M Griffiss
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

8.  Epidemiologic characteristics of an outbreak of serogroup C meningococcal disease and the public health response.

Authors:  P Houck; M Patnode; R Atwood; K Powell
Journal:  Public Health Rep       Date:  1995 May-Jun       Impact factor: 2.792

9.  Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice.

Authors:  Zhigang Jin; Chiayung Chu; John B Robbins; Rachel Schneerson
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

10.  Elaboration of a 3.6-kilodalton lipooligosaccharide, antibody against which is absent from human sera, is associated with serum resistance of Neisseria gonorrhoeae.

Authors:  H Schneider; J M Griffiss; R E Mandrell; G A Jarvis
Journal:  Infect Immun       Date:  1985-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.